1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety considerations with fibrate therapy.

      The American Journal of Cardiology

      Cholelithiasis, chemically induced, Clinical Trials as Topic, Clofibric Acid, adverse effects, pharmacology, therapeutic use, Creatinine, blood, Drug Therapy, Combination, Dyslipidemias, drug therapy, Evidence-Based Medicine, Humans, Hypolipidemic Agents, Kidney, drug effects, metabolism, Peroxisome Proliferator-Activated Receptors, agonists, Rhabdomyolysis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fibrates are an important class of drugs for the management of dyslipidemia. This class of drugs is generally well tolerated but is infrequently associated with several safety issues. Fibrates, most likely by an effect mediated by peroxisome proliferator-activated receptor-alpha, may reversibly increase creatinine and homocysteine but are not associated with an increased risk for renal failure in clinical trials. Fibrates are associated with a slightly increased risk (<1.0%) for myopathy, cholelithiasis, and venous thrombosis. In clinical trials, patients without elevated triglycerides and/or low high-density lipoprotein cholesterol (HDL) levels, fibrates are associated with an increase in noncardiovascular mortality. In combination with statins, gemfibrozil generally should be avoided. The preferred option is fenofibrate, which is not associated with an inhibition of statin metabolism. Clinicians are advised to measure serum creatinine before fibrate use and adjust the dose accordingly for renal impairment. Routine monitoring of creatinine is not required, but if a patient has a clinically important increase in creatinine, and other potential causes of creatinine increase have been excluded, consideration should be given to discontinuing fibrate therapy or reducing the dose.

          Related collections

          Author and article information

          Journal
          17368275
          10.1016/j.amjcard.2006.11.016

          Comments

          Comment on this article